Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer

Mechanistic/mammalian target of rapamycin (mTOR) has emerged as a new potential therapeutic target for gastric cancer. Rapamycin and rapamycin analogs are undergoing clinical trials and have produced clinical responses in a subgroup of cancer patients. However, monotherapy with rapamycin at safe dos...

Full description

Bibliographic Details
Main Authors: Weiqian Chen, Peng Zou, Zhongwei Zhao, Xi Chen, Xiaoxi Fan, Rajamanickam Vinothkumar, Ri Cui, Fazong Wu, Qianqian Zhang, Guang Liang, Jiansong Ji
Format: Article
Language:English
Published: Elsevier 2016-12-01
Series:Redox Biology
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2213231716301331